Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $81.96 USD
Change Today -0.13 / -0.16%
Volume 785.6K
CLVS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

clovis oncology inc (CLVS) Snapshot

Open
$81.84
Previous Close
$82.09
Day High
$85.91
Day Low
$81.24
52 Week High
04/16/15 - $94.88
52 Week Low
08/4/14 - $35.33
Market Cap
2.8B
Average Volume 10 Days
677.2K
EPS TTM
$-4.56
Shares Outstanding
34.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLOVIS ONCOLOGY INC (CLVS)

clovis oncology inc (CLVS) Related Businessweek News

No Related Businessweek News Found

clovis oncology inc (CLVS) Details

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

136 Employees
Last Reported Date: 02/27/15

clovis oncology inc (CLVS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $901.7K
Co-Founder, Chief Medical Officer and Executi...
Total Annual Compensation: $643.9K
Co-Founder, Chief Regulatory Officer and Exec...
Total Annual Compensation: $575.2K
Co-Founder, Chief Financial Officer, Executiv...
Total Annual Compensation: $575.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $473.4K
Compensation as of Fiscal Year 2014.

clovis oncology inc (CLVS) Key Developments

Clovis Oncology, Inc. Receives Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment

Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the company’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with BRCA-mutated tumors, inclusive of both germline BRCA (gBRCA) and somatic BRCA (sBRCA) mutations. Rucaparib is an oral, potent inhibitor of PARP1 and PARP2 being developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as BRCA-like or BRCAness. The Breakthrough Therapy designation was granted based on interim efficacy and safety results from two ongoing Phase 2 studies of rucaparib in ovarian cancer, including a Phase 2 study in women with gBRCA mutations, and the ARIEL2 treatment study. A clinical data update from the ARIEL2 study presented last week at the 2015 Annual Meeting on Women’s Cancer demonstrated that 70% (16/23) of evaluable BRCA-mutant patients achieved a RECIST and/or CA-125 response, and 65% (15/23) achieved a RECIST response. Responses were observed in both germline and somatic BRCA-mutant tumors.

Clovis Oncology, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Clovis Oncology, Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported operating loss of $53,890,000 compared to $28,494,000 a year ago. Loss before income taxes was $55,088,000 compared to $29,151,000 a year ago. Net loss was $54,907,000 or $1.62 per basic and diluted share compared to $29,203,000 or $0.92 per basic and diluted share for the fourth quarter of 2013. For the full year, the company reported revenue of $13,625,000. Operating loss was $158,459,000 compared to $83,767,000 a year ago. Loss before income taxes was $157,723,000 compared to $84,480,000 a year ago. Net loss was $160,031,000 or $4.72 per basic and diluted share compared to $84,532,000 or $2.95 per basic and diluted share a year ago.

Clovis Oncology, Inc. to Report Q4, 2014 Results on Feb 25, 2015

Clovis Oncology, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLVS:US $81.96 USD -0.13

CLVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLVS.
View Industry Companies
 

Industry Analysis

CLVS

Industry Average

Valuation CLVS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 204.5x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 148.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLOVIS ONCOLOGY INC, please visit www.clovisoncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.